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Objectives: To investigate the time-dependent changes in plasma levels of interleukin-6, C-reactive protein, and
tumor necrosis factor-α in patients with type A aortic dissection (TAAD) who received unoptimal medical
management since the onset of dissections.
Design and methods: Plasma levels of interleukin-6, C-reactive protein, and tumor necrosis factor-α were detected
by ELISA and immuno-turbidimetric assay in 92 TAAD patients at hospital admission. Blood samples from 78
patients with uncontrolled hypertension and 82 healthy volunteers were also analyzed as controls. The occurrence
of TAAD-related complication and its relationship with the plasma levels of these inflammatory biomarkers was
also investigated.
Results: The concentrations of inflammatory mediators were significant higher in TAAD than those in the
uncontrolled hypertension and the healthy group. The time to peak plasma level of IL-6.and TNF-α was shorter than
that of CRP in TAAD group. In the TAAD group, 51 patients suffered TAAD-related complications, and their plasma
level of CRP was significantly higher than that in patients without TAAD-related complications (94.5 ± 58.8 mg/L
versus 47.4 ± 47.8 mg/L, p < 0.001). Also, CRP levels strongly correlated with the value of PaO2/FiO2 ratio (r = −0.69,
p < 0.001) and creatinine (r = 0.60, p < 0.001). The time to the peak level of CRP was shorter and the duration of
persistently high CRP level was longer in the complication group than those in the complication-free group.
Conclusions: Elevated and persistently high levels of plasma CRP, IL-6 and TNF-α were associated with progressively
development of the TAAD. The changing pattern of CRP might be a marker for diagnosis and prophylactic
treatment of complications. Our findings suggested a critical role of the inflammation in the progression of
dissection and TAAD-related complications.
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The Stanford type A aortic dissection (TAAD) is a cata-
strophic cardiovascular condition associated with severe
morbidity and mortality [1,2]. Patients without optimal
medical treatment have a mortality rate of 50-68% dur-
ing the first 48 hours after an acute event, with a mean* Correspondence: mengwei11111@gmail.com
†Equal contributors
Department of Cardiovascular Surgery, West China Hospital, Sichuan
University, Guoxue Alley 37, Cheng du 610041, Sichuan, People’s Republic of
China
© 2015 Gu et al.; licensee BioMed Central. Thi
Attribution License (http://creativecommons.o
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.mortality of up to 1% per hour, and reaches as high as 90%
within 3 months [3]. Despite the continuous advances of
diagnostic technologies during recent years [4], it remains
difficult to assess the progression of TAAD accurately.
Aortic dissection is characterized by medial degeneration
with intimal tear and crossing of blood into the artery wall,
leading to the formation of a false lumen and subsequent
systemic inflammatory responses [5]. Interleukin-6 (IL-6),
C-reactive protein (CRP), and tumor necrosis factor-α
(TNF-α) are major pro-inflammatory cytokines, and their
increasing levels have been demonstrated to be closelys is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The distribution of patients with or without TAAD-related
complications.
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complications [6,7]. However, the expression of these in-
flammatory biomarkers might be significantly affected by
several anti-hypertensive and anti-inflammatory medica-
tions, and thus their clinical value might be greatly com-
promised [8]. Therefore, the present study was designed to
investigate the plasma levels of IL-6, CRP, and TNF-α in
TAAD patients who admitted without optimal medical
management since the onset of symptoms. In addition, the
potential relationship between the expression levels of
these inflammatory biomarkers and TAAD-related compli-
cations was also determined.
Methods
Patient profile
The present study was a prospective, single-center, ob-
servational study. From August 2013 to February 2014,
156 patients admitted with TAAD at West China hospital
were screened. Of these patients, 138 patients (88.5%) were
transferred from rural and community hospitals and pa-
tients there received unoptimal medical management. After
admission, all patients were managed according to current
guidelines and 118 patients (75.6%) were treated surgically.
Patients received stringent anti-hypertensive management,
or treatment with statins, angiotensin-converting enzyme
inhibitors or angiotensin receptor blocker within last
3 months at the time of enrollment were excluded. More-
over, patients with history of autoimmune or inflamma-
tory systemic disease were also excluded. Of the 156
patients screened for participation, 21 patients refused
participation in the study, 43 patients met at least one ex-
clusion criteria, leaving 92 patients in the study (TAAD
group). Meanwhile, 78 patients with uncontrolled hyper-
tension alone (uHT group) and 82 healthy volunteers
(Control group) selected among those attending our out-
patient department were also enrolled in the present
study. Our investigation was approved by the Institutional
Review Board of West China Hospital in compliance with
the Declaration of Helsinki (reference number: 2012150).
Written informed consent was obtained from all patients
before inclusion in this study.
Definitions and experimental protocol
The diagnosis of TAAD was confirmed in all patients ac-
cording to the Stanford classification. Patients were di-
vided according to the time of admission since the onset
of symptoms (<0.5 day for T1, 0.5-1 day for T2, 1–2
days for T3, 2–4 days for T4, 4–7 days for T5, 7–14 days
for T6, 14–30 days for T7, 30–60 days for T8, > 60 days
for T9) (Figure 1). The dissection was considered as acute
if the time from the onset of the symptoms to admission
was within 14 days, while chronic TAAD is that over
14 days. The uncontrolled hypertension was diagnosed by
a clinic record of systolic blood pressure ≥ 140 mmHg,and/or diastolic blood pressure ≥ 90 mmHg under the an-
tihypertensive treatment. Serum creatinine in patients
without a history of renal dysfunction exceeded 150% of
the normal high limit was considered to be TAAD-related
renal injury [9]. PaO2/FiO2 ratio ≤ 300 was considered to
be lung injury [10]. Other specifications of TAAD-related
complication were defined according to 2014 European
Society of Cardiology guidelines on the diagnosis and
treatment of aortic diseases [4].Assessment of plasma inflammatory biomarkers
Heparin-anticoagulant venous blood was drawn at ad-
mission from all the patients. The plasma was obtained
after centrifuging the blood at 1000 g for 15 min at 4°C
and then stored at −80°C for further analysis. The con-
centrations of plasma TNF-α and IL-6 were measured
and calculated by using ELISA technique (R&D Systems,
Minneapolis, MN, USA) according to the manufacturer’s
instructions. The plasma level of CRP was determined
by immuno-turbidimetric assay (Beckman Assay 360,
Bera, CA, USA). The detection limits were 0.5 pg/ml,
0.7 pg/ml and 0.17 mg/L for TNF -α, IL-6 and CRP,
respectively.Statistical analysis
Continuous variables are expressed as mean ± standard
deviation, and categorical data as percentages or absolute
numbers unless otherwise specified. Independent continu-
ous variables were compared by unpaired Student’s t test
for normally distributed data, and Mann–Whitney U-test
was used for the comparison of parameters that did not
exhibit a normal distribution. Categorical variables were
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other nonparametric tests as appropriate. The relationship
between the values of inflammatory biomarkers and the
incidence of TAAD-related complications was assessed by
Spearman’s correlation. Two-tailed p value less than 0.05
was considered statistically significant. Statistical ana-




Apart from the plasma levels of inflammatory cytokines
at admission, no significant differences were observed re-
garding age, sex and other clinical variables between the
TAAD group and the uHT group. In addition, patients in
the TAAD and uHT groups tended to be older than
healthy volunteers. Baseline data of the TAAD group and
other 2 control groups are summarized in Table 1.
Plasma levels of inflammatory cytokines at admission
The concentration of IL-6 was significantly higher in pa-
tients with TAAD than that in the uHT (50.41 ± 42.95 pg/









Age (year) 53.2 ± 11.2 55.8 ± 13.6 50.4 ± 10.2
Males, n (%) 69 (75.0) 52 (66.7) 56 (68.3)
Smoking history, n (%) 50 (54.3) 36 (46.2) 39 (47.6)
Hypertension, n (%) 75 (81.5) 78 (100) -
SBP, mmHg 165 ± 19* 158 ± 21* 112 ± 23




17 (18.5) 19 (24.4) -
Calcium channel bloker,
n (%)
21 (22.8) 18 (23.1) -
Alpha receptor blocker,
n (%)
9 (9.8) 5 (6.4) -
Total cholesterol
(mmol/l)
5.37 ± 1.22 5.35 ± 0.98 5.03 ± 1.24
Triglyceride (mmol/l) 1.42 ± 1.31 1.57 ± 1.34 1.43 ± 1.12
Hemoglobin (g/L) 119.3 ± 23.4 124.7 ± 21.8 128.5 ± 25.6
Plasma inflammatory
mediators
IL-6 (pg/ml) 50.41 ± 42.95*§ 5.82 ± 2.49 4.42 ± 2.12
CRP (mg/L) 68.02 ± 35.75*§ 4.68 ± 3.89 3.08 ± 2.46
TNF-α (pg/ml) 47.52 ± 28.46*§ 3.25 ± 1.06 2.37 ± 1.45
SBP, Systolic blood pressure; DBP, Diastolic blood pressure; IL-6, Interleukin-6;
CRP, C-reactive protein; TNF-α, Tumor necrosis factor-α; Values are mean ± SD;
*P < 0.05 vs healthy group, §P < 0.05 vs hypertension group.(50.41 ± 42.95 pg/ml vs. 4.42 ± 2.12 pg/ml, p < 0.05). The
level of CRP was significantly elevated in TAAD patients
(68.02 ± 35.75 mg/L) compared with those in the uHT
(4.68 ± 3.89 mg/L) and Control groups (3.08 ± 2.46 mg/L).
Similarly, a significant increase of the plasma level of
TNF-α was detected in TAAD patients (Table 1). The time
to peak plasma level of IL-6.and TNF-α was shorter than
that of CRP (Figure 2).
The occurrence of TAAD-related complications
Of the 92 TAAD patients recruited in our study (Table 2),
51 patients (55.4%) suffered complications, and the distri-
bution of patients admitted at different time points after
symptoms onset was shown in Figure 1. Patients with
TAAD-related complications were slightly older than pa-
tients in the no-complications cohort. Plasma CRP in the
complication group was significantly higher than that in the
complication-free group (94.5 ± 58.8 mg/L versus 47.4 ±
47.8 mg/L, p < 0.001). Of the 51 patients evaluated with 88
complications, the most common complications were renal
dysfunction, lung injury and aortic regurgitation (as shown
in Table 3).
The values of inflammatory biomarkers in relation to
complications
In TAAD patients, a significant negative correlation was
found between CRP expression and PaO2/FiO2 ratio
(r = −0.69, P < 0.001) (Figure 3A), whereas the relation-
ship between the plasma level of CRP and serum cre-
atinine demonstrated a negative correlation (r = −0.60,
P < 0.001) (Figure 3B). The levels of TNF-α and IL-6
were not significantly correlated with the value of PaO2/
FiO2 ratio and serum creatinine. The time-dependentFigure 2 Plasma levels of IL-6, CRP and TNF-α in different
time course.
Table 2 Demographics of dissection patients with or
without complications
Variable Complication (+)
group (n = 51)
Complication (−)
group (n = 41)
P value
Age(years) 61.8 ± 14.4 59.9 ± 13.8 0.458
Male, n (%) 40 (78.4) 29 (70.7) 0.244
Admission
SBP, mmHg 142.5 ± 27.5 138.4 ± 32.7 0.211
DBP, mmHg 76.5 ± 15.8 74.3 ± 17.5 0.583
Hemoglobin (g/L) 128.4 ± 24.5 125.3 ± 19.8 0.634
Total cholesterol
(mg/dl)
170.4 ± 37.8 154.7 ± 24.5 0.187
Triglyceride (mmol/L) 1.53 ± 1.05 1.46 ± 0.98 0.359
CRP (mg/L) 83.2 ± 60.7 41.9 ± 41.3 <0.001
SBP, Systolic blood pressure; DBP, Diastolic blood pressure.
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and complication-free group (41 cases) were shown in
Figure 4. In the complication (−) group, the time to peak
CRP (average 120.5 mg/L) was in T4 and then declined
immediately. In the complication group, the CRP pattern
reached to peak (average 140.5 mg/L) in T3 when earlier
than complication-free group. Of note, there was a wider
range time (T3-T5) of peak CRP in the complication
group than that in the complication-free group.Discussion
In the present study, we showed that the plasma levels
of CRP, IL-6 and TNF-α were significantly increased in
acute TAAD patients (before T6) compared to those in
uncontrolled hypertension and healthy volunteers. The
expression levels of these inflammatory cytokines peaked
at the acute phase of TAAD and gradually declined at
different stages of TAAD progression. More importantly,Table 3 Distribution of TAAD-related complications in the
complication (+) group
Complications, n (%)
Total Complications 88 (100.0)
Aortic regurgitation 13 (14.8)
Myocardial ischemia/infarction 7 (8.0)
Congestive heart failure 6 (6.8)
Large pleural effusions 6 (6.8)
Syncope 7 (8.0)
Neurological symptoms 8 (9.1)
Mesenteric ischemia 4 (4.5)
Renal dysfunction 22 (25.0)
Lung injury 15 (17.0)the time-dependent changes of CRP level, particularly
the CRP pattern provided more information in terms of
prediction of TAAD-related inflammatory complications.
Our data strongly suggested a critical role of inflamma-
tory responses in the development of TAAD and result-
ant systemic complications.
CRP, a circulating and nonspecific inflammatory bio-
marker, has been shown to be elevated and varied with dif-
ferent stages of aortic dissection [7,11-13]. Peak plasma
level of CRP at admission is regarded as a predictor of ad-
verse short- and long-term events in patients with TAAD
[7]. Consistent with previous studies, we demonstrated a
time-dependent change of CRP, which peaked in patients
admitted on the 4th day (T5) after symptoms onset and
declined thereafter. Secondly, because CRP is a non-
specific inflammatory marker, it reflects not only the
TAAD itself but also systemic inflammatory responses,
leadig to pulmonary or renal injury [14,15]. More import-
antly, in the complication group, the time to peak CRP
was earlier and the duration of peak CRP was longer than
in the complication-free group. These findings indicated
a contributory role of inflammation in the progression
of dissection, and further suggested that TAAD patients
with persistently high CRP levels during the first 7 days
from symptoms onset might be of great risk for major
adverse events.
Significant elevation of IL-6 and TNF-α levels were
also detected in patients admitted at the acute phase of
TAAD (before T7) when compared with other 2 control
groups. However, in patients with chronic TAAD (T7-
T9), no significant difference between the chronic TAAD
subgroup and the uHT group was observed. In addition,
the changing patterns of these two inflammatory cyto-
kines were slightly different. Nevertheless, the plasma
levels of IL-6 and TNF-α both peaked during the 12 hrs
to 24 hrs period, which was much earlier than CRP.
Current evidence demonstrated a significant infiltration
of macrophages and neutrophils in the dissected aortic
wall [16]. These recruited leukocytes could release a
series of pro-inflammatory cytokines, which would fur-
ther accelerate the progression of dissection and lead to
systemic complications. Since CRP is produced mainly
in liver by the stimulation of many inflammatory cytokines
[17], it is understandable that the plasma levels of
leukocytes-derived cytokines like IL-6.and TNF-α peaked
earlier than CRP.
In the current study, the average values of CRP, IL-6
and TNF-α in patients with chronic TAAD and hyperten-
sion tended to be higher than those in the healthy controls
(Chronic TAAD vs. Healthy, P = 0.06; uHT vs. Healthy,
P = 0.09). As the mechanism of TAAD remained large
unknown [18], our findings accordingly confirmed that
inflammation was closely involved into the pathogenesis
of hypertension-induced aortic wall injury and the
Figure 3 The correlations between CRP and PaO2/FiO2 ratio (A) and serum creatinine (B).
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ant to follow up the plasma levels of inflammatory cyto-
kines in patients with uncontrolled hypertension. If
these biomarkers do not decrease after stringent control
of blood pressure, there could be a potential risk of
aneurysmal dilatation of the aorta that might lead to future
dissection, and therefore, additional anti-inflammatory
medications like statins for such patients might be a rea-
sonable choice.Limitation
There are several limitations in the present study. Firstly,
because of the absence of serial blood samples spanning
the first few hours period of TAAD progression, it is diffi-
cult for us to fully elucidate the changing patterns of CRP,
IL-6.and TNF-α and their clinical values for diagnosis and
prophylactic treatment of complications. Secondly, in order
to avoid significant influences of several known drugs on
the expression levels of inflammatory biomarkers, we
Figure 4 The plasma levels of CRP in the complication (+) group
and complication (−) group. The time to peak level of CRP was
shorter and the duration of persistently high CRP level was longer in
the complication (+) group than those in the complication (−) group.
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ment. However, the rationality of the inclusion criteria re-
mains to be fully discussed. Nevertheless, to the best of
our knowledge, the present study firstly provided infor-
mation on the changes of the inflammatory biomarkers,
which were less affected by anti-hypertensive and anti-
inflammatory medications. In addition, we observed
such a surprisingly high percentage of inappropriately
treated patients from rural areas (78/92, 84.7%), indicat-
ing the urgent necessity and importance of the primary
prevention for hypertension-related disease in the rural
areas of China. Although this study was strengthened by
its prospective design, the patient population is relatively
small, and we cannot exclude the possibility that other
confounders such as genetic factors (Marfan syndrome
etc.), smoking, diabetes and use of β-blockers and missed
medication history may have influenced our results.
Conclusions
In this small sample size, prospective study, we demon-
strated that increased plasma CRP, IL-6 and TNF-α were
significantly associated with TAAD. More importantly,
the changing pattern of CRP might be a marker for diag-
nosis and prophylactic treatment of complications. Taken
together, our data clearly indicated the critical role of in-
flammation in the progression of dissection and TAAD-
related complications.
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